Search

ENPNewswire-February 10, 2025--Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (C)2025 ENPublishing - http://www.enpublishing.co.uk Release date- 07022025 - MALVERN - Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or [...]

(EDGAR Online via COMTEX) -- false 0001477845 0001477845 2025-02-03 2025-02-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section [...]

(EDGAR Online via COMTEX) -- false 0001477845 0001477845 2025-02-05 2025-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section [...]

ENPNewswire-February 6, 2025--Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease (C)2025 ENPublishing - http://www.enpublishing.co.uk Release date- 05022025 - MALVERN - Annovis Bio [...]

ENPNewswire-January 15, 2025--Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection (C)2025 ENPublishing - http://www.enpublishing.co.uk Release date- 14012025 - MALVERN - Annovis [...]

ENPNewswire-January 8, 2025--Annovis Bio Inc. - FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway (C)2025 ENPublishing - http://www.enpublishing.co.uk Release date- 07012025 - MALVERN - [...]